{"organizations": [], "uuid": "fba1da9da3020e14ccb047aaebe334c0bfc3dc6c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/8", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/15/globe-newswire-portola-pharmaceuticals-to-announce-fourth-quarter-and-full-yeara2017-financial-results-and-host-conference-call-on.html", "country": "US", "domain_rank": 767, "title": "Portola Pharmaceuticals to Announce and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-16T00:05:00.000+02:00", "replies_count": 0, "uuid": "fba1da9da3020e14ccb047aaebe334c0bfc3dc6c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/15/globe-newswire-portola-pharmaceuticals-to-announce-fourth-quarter-and-full-yeara2017-financial-results-and-host-conference-call-on.html", "ord_in_thread": 0, "title": "Portola Pharmaceuticals to Announce and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "san francisco", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "portola pharmaceuticals", "sentiment": "neutral"}, {"name": "portola pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "nasd", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}, {"name": "ptla", "sentiment": "none"}, {"name": "about portola pharmaceuticals, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SOUTH SAN FRANCISCO, Calif., Portola Pharmaceuticals, Inc. ® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results and full year ended December 31, 2017, and provide a general business overview on Wednesday, February 28, 2018, at 4:30 p.m. ET (1:30 p.m. PT).\nConference Call Details\nThe live conference call on Wednesday, February 28, 2018, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 4893459. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com . It will be archived for 30 days following the call.\nAbout Portola Pharmaceuticals, Inc.\nPortola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa ® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.\nInvestor Contact:\nCara Miller\nPortola Pharmaceuticals\nir@portola.com\nMedia Contact:\nLaurie Masonson\nW2O Group\nlmasonson@w2ogroup.com\nSource:Portola Pharmaceuticals, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=P-Mgy2PSr5UqzOGSu86IrVZRsGF3B8YzLWnmqMlbaWYpbOy_troT662dabJFzz3oH5QNI3V_jJ8WtFoZXbjg23fm5UTzMcAMK2tLMcVVoa1vrSV8M5wlVlEfviVgl_QXaZmyR9TTY8lug67Yb51gDc_D5xj5NNaHvvbs6qKPPduIoGAOUptm9vJHH541eRjYnld-USpcKkuvQNBgdz4Z_pgaG94sVAu4EKMCVq3baK8F9PtVfHOw4GHLTF-BHX_otj8gD7UQ84QPOhaEoHym7g==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/1bfebfe9-504a-4b64-9f71-2f04865f8d15", "https://www.globenewswire.com/Tracker?data=P-Mgy2PSr5UqzOGSu86Irc9X8EgUFlTssXuzAfegTsKhoAhi4cX3W9b9IIjj3MbPJ2qyXCBbzg4h-PxAEdINg2hUrWip_SjxaXsSKOKufeG9XBTFCsg1MA-V0eObdJIBXwUxPL-LCvqyP7hSD_HXdy-aI4MUV-MMCvSIKpaDyKsjZOWbBrcKezueIZ4PKlEHovdIF7El_ywobNacW1mXSbbnemrSD-i847PGokt75KrcxEG4CwcrPP5d2g-sv2S5xf-dqystJiwHPRwbMKesnQ==", "https://www.globenewswire.com/Tracker?data=2z8NR0oO_--Qakieu_stXm_ovW3rkJsZKthuEvcX1dFGKCGrnn2D7owCfrY9m3t5bol-pBlg2yeWEtSbp_FWwb73CVhUPJwU9nvy1Jt3iYc=", "https://www.globenewswire.com/Tracker?data=NTi2cZARmnvjvLaM2LkkYDwLt_ee0SrUXy0DVQj1_s3cVbEX6Rke01Cpupota_Hvlp016SLiWl5hKQH1jfU0VQ=="], "published": "2018-02-16T00:05:00.000+02:00", "crawled": "2018-02-16T05:31:19.007+02:00", "highlightTitle": ""}